Jason Luke, MD, FACP
Associate Director for Clinical Research and Director, Immunotherapy and Drug Development Center / Associate Professor of Medicine
UPMC Hillman Cancer Center / University of Pittsburgh
Jason Luke, MD, FACP, is an associate professor of Medicine at the University of Pittsburgh and UPMC Hillman Cancer Center, where he is associate director for Clinical Research and the director of the Immunotherapy and Drug Development Center (Phase I). Dr Luke specializes in early phase drug development for solid tumors (particularly novel immunotherapeutics and biomarkers of immunotherapy activity) as well as the management of melanoma.Dr Luke received his medical degree from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued internship and residency at the Boston University Medical Center followed by medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City. Following fellowship, Dr Luke was a tenure-track, Type 1 Instructor in Medicine at Harvard Medical School as well as staff physician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Thereafter, Dr Luke was an assistant professor at the University of Chicago.Dr Luke is one of the foremost international investigators in the realm of immuno-oncology, having led clinical trials of immunotherapies including but not limited to anti-PD1/L1, CTLA4, many secondary checkpoints, bispecific approaches (checkpoint, CD3 and cytokine), metabolism modifiers (IDO, A2Ar/CD73/CD39 and arginase), innate agonists of STING, TLRs and oncolytic virus as well as solid tumor cellular therapies (TCRs and CART). In melanoma, Dr Luke has designed and led two practice changing trials determining the role of anti-PD1 + CTLA4 after initial anti-PD1 failure (compendium listed in the NCCN) and altering the landscape of melanoma oncology practice across dermatology, surgery and medical oncology via establishment of modern adjuvant therapy with anti-PD1 for node negative stage IIB/C disease (leading to FDA/EMA approval). Dr Luke has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy.Dr Luke’s major translational research focus leverages large scale informatics to advance cancer immunotherapy. Dr Luke is currently senior editor at Clinical Cancer Research, section editor at the Journal for Immunotherapy of Cancer and skin cancer sectional editor for the American Cancer Society journal Cancer. Dr Luke is actively involved in several professional societies including SITC -- where he sits on the Board of Directors -- AACR, ASCO and the Society for Melanoma Research, having served on the scientific program committees for each. Dr Luke leads an R01 funded laboratory, he is co-PI for the Pittsburgh UM1 LAO and is project 3 clinical co-leader of the Pittsburgh Skin Cancer P50 SPORE, in addition to multiple private and state awards.Dr Luke has received several awards for research and clinical care including the Melanoma Research Foundation Humanitarian Award, Crain’s 40 under 40, DOD Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Investigator Awards from the Melanoma Research Alliance, the Cancer Research Foundation and the Conquer Cancer Foundation of ASCO.Dr Luke has been the leader of the Melanoma Committee for the American Society of Clinical Oncology and has held leadership positions within the Society for Immunotherapy of Cancer. Dr Luke is a member of the Melanoma Committee of the Eastern Cooperative Oncology Group and the Experimental Therapeutics Committee of the Alliance for Clinical Trials in Oncology. Dr Luke is also a member of the American Association for Cancer Research and Society for Melanoma Research.
